Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
8 Jan 24
25-NSE
Exchange delisting
12 Oct 23
8-K
Departure of Directors or Certain Officers
14 Sep 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Jul 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2022 FY
Annual report (amended)
25 Apr 23
8-K
Other Events
19 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
8-K
Other Events
2 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Feb 23
8-K
Entry into a Material Definitive Agreement
22 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Humanigen Reports Third Quarter 2022 Financial Results
14 Nov 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Oct 22
8-K
Departure of Directors or Certain Officers
29 Sep 22
8-K
Departure of Directors or Certain Officers
2 Sep 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Aug 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
Humanigen Reports Second Quarter 2022 Financial Results
12 Aug 22
8-K
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
26 Jul 22
8-K
Humanigen receives preliminary topline data from NIH/NIAID study of lenzilumab in ACTIV-5/BET-B
13 Jul 22
8-K
Other Events
30 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
8-K
Humanigen Reports First Quarter 2022 Financial Results
5 May 22
10-Q
2022 Q1
Quarterly report
5 May 22
EFFECT
Notice of effectiveness
15 Apr 22
424B5
Prospectus supplement for primary offering
14 Apr 22
8-K
Other Events
12 Apr 22
DEFA14A
Additional proxy soliciting materials
12 Apr 22
DEF 14A
Definitive proxy
12 Apr 22
8-K
Regulation FD Disclosure
12 Apr 22
CORRESP
Correspondence with SEC
12 Apr 22
UPLOAD
Letter from SEC
7 Mar 22
S-3
Shelf registration
1 Mar 22
10-K
2021 FY
Annual report
28 Feb 22
8-K
Humanigen Reports Year-End 2021 Financial Results
28 Feb 22
8-K
Other Events
5 Jan 22
Latest ownership filings
4
Dale Chappell
20 Oct 23
SC 13G/A
Murchinson Ltd.
1 Feb 23
SC 13G/A
Valiant Capital Management, L.P.
10 Aug 22
4
Cheryl Buxton
29 Jul 22
4
John Hohneker
29 Jul 22
4
RONALD BARLIANT
29 Jul 22
4
Adrian Kilcoyne
29 Jul 22
4
Dale Chappell
29 Jul 22
4
Rainer J. Boehm
29 Jul 22
4
Edward P. Jordan
29 Jul 22
4
TIMOTHY E MORRIS
29 Jul 22
4
Yili Kevin Xie
29 Jul 22
4
Cameron Durrant
29 Jul 22
4
Dale Chappell
20 May 22
SC 13G
BlackRock Inc.
9 May 22
SC 13D/A
Cheval Holdings, Ltd.
17 Mar 22
4
Dale Chappell
15 Mar 22
4
Adrian Kilcoyne
14 Mar 22
4
Dale Chappell
10 Mar 22
4
Dale Chappell
4 Mar 22
4
Cameron Durrant
4 Mar 22
4
Edward P. Jordan
4 Mar 22
SC 13G/A
Valiant Capital Management, L.P.
14 Feb 22
SC 13G
BlackRock Inc.
4 Feb 22
4
Cameron Durrant
14 Jan 22
4
Dale Chappell
14 Jan 22
4
TIMOTHY E MORRIS
14 Jan 22
4
Edward P. Jordan
14 Jan 22
4
Adrian Kilcoyne
14 Jan 22
SC 13G/A
STATE STREET CORP
10 Jan 22
4
Yili Kevin Xie
4 Jan 22
4
Cheryl Buxton
4 Jan 22
4
Rainer J. Boehm
4 Jan 22
4
RONALD BARLIANT
4 Jan 22
4
John Hohneker
4 Jan 22
4
Dale Chappell
4 Jan 22
4
Edward P. Jordan
4 Jan 22
4
TIMOTHY E MORRIS
4 Jan 22
4
Adrian Kilcoyne
4 Jan 22
4
Cameron Durrant
4 Jan 22